About nVector, Inc

nVector’s next-generation gene therapy technology is poised to enable revolutionary treatments for central nervous systems (CNS) diseases such as Alzheimer’s, Parkinson’s, ALS, and traumatic brain injury. To drive this capability, the company has brought on board Fredric Manfredsson, Ph.D. as Chief Scientific Officer to team with Robert Bowser, Ph.D., nVector’s Chairman of the Board. Together they are directing the development of nVector’s Adeno-Associated Virus platform, which features the fiView more